Privia Health Group (PRVA) Stock Forecast & Price Target

Compare

211 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PRVA Analyst Ratings

Strong Buy

13 Buy

2 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Privia

Health Group

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PRVA Stock 12 Month Forecast

Average Price Target

$30.69

▲(29.82% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Privia Health Group in the last 3 months. The average price target is $30.69 with a high forecast of $35.00 and a low forecast of $23.00. The average price target represents a 29.82% change from the last price of $23.64.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","36":"$36","21.75":"$21.8","26.5":"$26.5","31.25":"$31.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,21.75,26.5,31.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.1,24.93846153846154,25.77692307692308,26.615384615384617,27.453846153846154,28.292307692307695,29.130769230769232,29.96923076923077,30.807692307692307,31.646153846153847,32.48461538461538,33.323076923076925,34.16153846153846,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.1,24.606923076923078,25.113846153846154,25.620769230769234,26.12769230769231,26.634615384615387,27.141538461538463,27.64846153846154,28.155384615384616,28.662307692307692,29.169230769230772,29.67615384615385,30.183076923076925,{"y":30.69,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.1,24.015384615384615,23.930769230769233,23.846153846153847,23.761538461538464,23.676923076923078,23.592307692307692,23.50769230769231,23.423076923076923,23.338461538461537,23.253846153846155,23.16923076923077,23.084615384615386,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.31,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.83,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.54,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$30.69

Lowest Price Target$23.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jailendra Singh

Truist Financial

Buy

―

Reiterated

12/17/25

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN)

Lisa Gill

J.P. Morgan

$33

Buy

39.59%

Upside

Reiterated

11/13/25

J.P. Morgan Reaffirms Their Buy Rating on Privia Health Group (PRVA)

Sean Dodge

BMO Capital

$30

Buy

26.90%

Upside

Initiated

11/12/25

BMO Capital Highlights Privia Health Group's Strong Growth Potential and Differentiated Risk Management in Value-Based Care

Richard Close

Canaccord Genuity

$32→$34

Buy

43.82%

Upside

Reiterated

11/11/25

Analysts' Top Healthcare Picks: Viking Therapeutics (VKTX), Privia Health Group (PRVA)

Andrew Mok CFA

Barclays

$22→$23

Hold

-2.71%

Downside

Reiterated

11/07/25

Privia Health price target raised to $23 from $22 at BarclaysPrivia Health price target raised to $23 from $22 at Barclays

Elizabeth Anderson CFA

Evercore ISI

$28→$30

Buy

26.90%

Upside

Reiterated

11/07/25

Privia Health Group (PRVA) Gets a Buy from Evercore ISI

Constantine Davides

Citizens JMP

$30→$31

Buy

31.13%

Upside

Reiterated

11/07/25

Privia Health price target raised to $31 from $30 at Citizens JMPPrivia Health price target raised to $31 from $30 at Citizens JMP

Ryan Daniels

William Blair

Buy

―

Reiterated

11/06/25

Privia Health Group: Strong Financial Performance and Strategic Positioning Drive Buy Rating

Matthew Shea

Needham

$30

Buy

26.90%

Upside

Reiterated

11/06/25

Analysts Are Bullish on These Healthcare Stocks: Collegium Pharmaceutical (COLL), Privia Health Group (PRVA)

Ryan Langston

TD Cowen

$30

Buy

26.90%

Upside

Reiterated

11/06/25

Privia Health Group: Strong Financial Performance and Strategic Growth Justify Buy Rating

Unknown Analyst

Citi

Not Ranked

Citi

$32

Buy

35.36%

Upside

Reiterated

10/21/25

Citi Reaffirms Their Buy Rating on Privia Health Group (PRVA)

A.J. Rice

UBS

$31

Buy

31.13%

Upside

Reiterated

09/25/25

Strategic Acquisition Boosts Privia Health's Growth Potential with Evolent Health's ACO Business

Michael Craig Jones

Bank of America Securities

$27

Hold

14.21%

Upside

Reiterated

09/24/25

Privia Health Group: Hold Rating Amid Growth Prospects and Integration Risks Post-Evolent Health Acquisition

Jessica Tassan

Piper Sandler

$35

Buy

48.05%

Upside

Reiterated

09/24/25

Piper Sandler Remains a Buy on Privia Health Group (PRVA)

Whit Mayo

Leerink Partners

$33

Buy

39.59%

Upside

Reiterated

09/23/25

Leerink Partners Keeps Their Buy Rating on Privia Health Group (PRVA)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jailendra Singh

Truist Financial

Buy

―

Reiterated

12/17/25

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN)

Lisa Gill

J.P. Morgan

$33

Buy

39.59%

Upside

Reiterated

11/13/25

J.P. Morgan Reaffirms Their Buy Rating on Privia Health Group (PRVA)

Sean Dodge

BMO Capital

$30

Buy

26.90%

Upside

Initiated

11/12/25

BMO Capital Highlights Privia Health Group's Strong Growth Potential and Differentiated Risk Management in Value-Based Care

Richard Close

Canaccord Genuity

$32→$34

Buy

43.82%

Upside

Reiterated

11/11/25

Analysts' Top Healthcare Picks: Viking Therapeutics (VKTX), Privia Health Group (PRVA)

Andrew Mok CFA

Barclays

$22→$23

Hold

-2.71%

Downside

Reiterated

11/07/25

Privia Health price target raised to $23 from $22 at BarclaysPrivia Health price target raised to $23 from $22 at Barclays

Elizabeth Anderson CFA

Evercore ISI

$28→$30

Buy

26.90%

Upside

Reiterated

11/07/25

Privia Health Group (PRVA) Gets a Buy from Evercore ISI

Constantine Davides

Citizens JMP

$30→$31

Buy

31.13%

Upside

Reiterated

11/07/25

Privia Health price target raised to $31 from $30 at Citizens JMPPrivia Health price target raised to $31 from $30 at Citizens JMP

Ryan Daniels

William Blair

Buy

―

Reiterated

11/06/25

Privia Health Group: Strong Financial Performance and Strategic Positioning Drive Buy Rating

Matthew Shea

Needham

$30

Buy

26.90%

Upside

Reiterated

11/06/25

Analysts Are Bullish on These Healthcare Stocks: Collegium Pharmaceutical (COLL), Privia Health Group (PRVA)

Ryan Langston

TD Cowen

$30

Buy

26.90%

Upside

Reiterated

11/06/25

Privia Health Group: Strong Financial Performance and Strategic Growth Justify Buy Rating

Unknown Analyst

Citi

Not Ranked

Citi

$32

Buy

35.36%

Upside

Reiterated

10/21/25

Citi Reaffirms Their Buy Rating on Privia Health Group (PRVA)

A.J. Rice

UBS

$31

Buy

31.13%

Upside

Reiterated

09/25/25

Strategic Acquisition Boosts Privia Health's Growth Potential with Evolent Health's ACO Business

Michael Craig Jones

Bank of America Securities

$27

Hold

14.21%

Upside

Reiterated

09/24/25

Privia Health Group: Hold Rating Amid Growth Prospects and Integration Risks Post-Evolent Health Acquisition

Jessica Tassan

Piper Sandler

$35

Buy

48.05%

Upside

Reiterated

09/24/25

Piper Sandler Remains a Buy on Privia Health Group (PRVA)

Whit Mayo

Leerink Partners

$33

Buy

39.59%

Upside

Reiterated

09/23/25

Leerink Partners Keeps Their Buy Rating on Privia Health Group (PRVA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Privia Health Group

1 Month

xxx

Success Rate

6/13 ratings generated profit

Average Return

+2.52%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 46.15% of your transactions generating a profit, with an average return of +2.52% per trade.

3 Months

xxx

Success Rate

6/11 ratings generated profit

Average Return

-2.10%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of -2.10% per trade.

1 Year

Constantine DavidesCitizens JMP

Success Rate

10/11 ratings generated profit

Average Return

+7.36%

reiterated a buy rating last month

Copying Constantine Davides's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +7.36% per trade.

2 Years

xxx

Success Rate

10/11 ratings generated profit

Average Return

+10.22%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +10.22% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRVA Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PRVA has received 16 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. PRVA average Analyst price target in the past 3 months is 30.69.

Each month's total comprises the sum of three months' worth of ratings.

PRVA Financial Forecast

PRVA Earnings Forecast

Next quarter’s earnings estimate for PRVA is $0.03 with a range of $0.00 to $0.05. The previous quarter’s EPS was $0.05. PRVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year PRVA has Performed in-line its overall industry.

PRVA Sales Forecast

Next quarter’s sales forecast for PRVA is $514.47M with a range of $493.00M to $552.10M. The previous quarter’s sales results were $580.42M. PRVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year PRVA has Performed in-line its overall industry.

PRVA Stock Forecast FAQ

What is PRVA’s average 12-month price target, according to analysts?

Based on analyst ratings, Privia Health Group’s 12-month average price target is 30.69.

What is PRVA’s upside potential, based on the analysts’ average price target?

Privia Health Group has 29.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PRVA a Buy, Sell or Hold?

Privia Health Group has a consensus rating of Strong Buy which is based on 13 buy ratings, 2 hold ratings and 0 sell ratings.

What is Privia Health Group’s price target?

The average price target for Privia Health Group is 30.69. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $23.00. The average price target represents 29.82% Increase from the current price of $23.64.

What do analysts say about Privia Health Group?

Privia Health Group’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of PRVA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Privia Health Group (PRVA) Stock Forecast & Price Target

PRVA Analyst Ratings

PRVA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Privia Health Group

PRVA Analyst Recommendation Trends

PRVA Financial Forecast

PRVA Earnings Forecast

PRVA Sales Forecast

PRVA Stock Forecast FAQ

Detailed List of Analyst Forecasts